Medicinal composition containing bilobalide B and vitamin K antagonist as well as preparation method and application of medicinal composition

A ginkgolide and composition technology, applied in the field of pharmaceutical compositions containing ginkgolide B, can solve the problems of poor platelet aggregation and curative effect, and reduce natural drug resistance and bleeding risk, mechanism of action Clear, simple-component effects

Active Publication Date: 2016-04-06
CHENGDU BAIYU PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, long-term use of warfarin can lead to patient tolerance and poor curative effect
How to overcome the poor effect of warfarin alone in inhibiting platelet aggregation needs to be solved urgently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing bilobalide B and vitamin K antagonist as well as preparation method and application of medicinal composition
  • Medicinal composition containing bilobalide B and vitamin K antagonist as well as preparation method and application of medicinal composition
  • Medicinal composition containing bilobalide B and vitamin K antagonist as well as preparation method and application of medicinal composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Ginkgolide B10 parts

[0027] Warfarin 5 parts

[0028] Pharmaceutically acceptable conventional excipients

[0029] After the above raw materials are mixed, add pharmaceutically acceptable conventional adjuvants and prepare tablets according to conventional techniques.

Embodiment 2

[0031] Ginkgolide B8 parts

[0032] Warfarin 7.5 parts

[0033] Pharmaceutically acceptable conventional excipients

[0034] After mixing the above-mentioned raw materials, add conventional pharmaceutically acceptable auxiliary materials to prepare capsules or soft capsules according to conventional processes.

Embodiment 3

[0036] Ginkgolide B12 parts

[0037] Warfarin 2.5 parts

[0038] Pharmaceutically acceptable conventional excipients

[0039] After the above-mentioned raw materials are mixed, a pharmaceutically acceptable conventional auxiliary material is added to prepare a pill according to a conventional process.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicinal composition containing bilobalide B. The medicinal composition contains bilobalide B and a vitamin K antagonist. The invention further provides a preparation method and an application of the medicinal composition. The experiment proves that bilobalide B can obviously promote the anti-platelet aggregation function of warfarin, also can eliminate/reduce the natural drug resistance of a patient generated due to only use of warfarin, and enhance the affinity between the liver receptor of a patient and warfarin, and bilobalide B and warfarin have the synergistic interaction. The medicinal composition is novel in formula, simple in components, definite in action mechanism and obvious in curative effect, tolerance is difficultly generated, and industrial production can be realized.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing ginkgolide B. Background technique [0002] Warfarin is an indirect-acting coumarin-based oral anticoagulant, a dicoumarin derivative with a chemical structure of 3-(a-phenylacetone)-4-hydroxycoumarin. It has no anticoagulant effect in the test tube, that is, it does not participate in in vitro anticoagulant blood, and exerts anticoagulant effect by inhibiting the synthesis of coagulation factors II, VII, IX, and X in liver cells by inhibiting vitamin K. The carboxylase in liver microsomes can convert the glutamic acid of the above coagulation factors into γ-carboxyglutamic acid, which can then combine with calcium ions to exert its coagulation activity. The function of this drug is to inhibit carboxylase, and it has no direct antagonism effect on the above-mentioned factors that have been synthesized. It must wait for these factors to be relatively exhausted in the body before it can ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61P7/02A61K31/365
Inventor 孙毅
Owner CHENGDU BAIYU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap